DalCor Pharmaceuticals

DalCor Pharmaceuticals, established in 2015, is a biopharmaceutical company specializing in precision medicine for cardiovascular diseases. Headquartered in Sarasota, Florida, with additional offices in Montreal, Zug, and Leatherhead, the company develops and commercializes targeted treatments based on patients' genetic profiles. DalCor's lead product, dalcetrapib, a cholesterol ester transfer protein inhibitor, is designed to reduce cardiovascular events in patients with a specific ADCY9 genetic profile, as demonstrated in a pharmacogenomics analysis of the dal-Outcomes study. The company holds a worldwide exclusive license for dalcetrapib and the ADCY9 genetic marker from Roche.